"Based in Colorado Springs, Colorado, Peak Gastroenterology Associates, PC, provides extraordinary gastrointestinal care with unparalleled customer service. We use evidence-based medicine, state-of-the-art equipment and compassion; seek to emerge as leaders in the field by participating in national organizations, publishing national guidelines, giving lectures and embracing innovative treatments to offer the best care possible; leverage performance and outcome measures to provide quality and accountability; and recruit quality providers by creating a collegial and professional work environment to decrease wait times and facilitate a team approach."

During the past decade, Peak Gastroenterology Associates conducted 45 clinical trials. In the 10-year time frame, 45 clinical trials started and 19 clinical trials were completed, i.e. on average, 42.2% percent of trials that started reached the finish line to date. In the past 5 years, 20 clinical trials started and 19 clinical trials were completed. i.e. 95% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Peak Gastroenterology Associates" #1 sponsor was "Celgene" with 7 trials, followed by "Pfizer" with 5 trials sponsored, "Shire" with 5 trials sponsored, "Allergan" with 4 trials sponsored and "Hoffmann-La Roche" with 4 trials sponsored. Other sponsors include 16 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Peak Gastroenterology Associates" #1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 3 trials as a collaborator, "Allergan Sales, LLC" with 1 trials as a collaborator, "ICON Clinical Research" with 1 trials as a collaborator and "Triangle Biostatistics" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Peak Gastroenterology Associates" are "Ulcerative Colitis" (10 trials), "Crohn Disease" (8 trials), "Crohn's Disease" (6 trials), "Eosinophilic Esophagitis" (5 trials) and "Gastroparesis" (4 trials). Many other conditions were trialed in "Peak Gastroenterology Associates" in a lesser frequency.

Most popular intervention types in "Peak Gastroenterology Associates" are "Drug" (43 trials), "Other" (7 trials), "Biological" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (30 trials), "Etrasimod" (5 trials), "Etrolizumab" (4 trials), "Ontamalimab" (4 trials) and "Ozanimod" (3 trials). Other intervention names were less common.

The vast majority of trials in "Peak Gastroenterology Associates" are 46 trials for "All" genders.

Currently, there are NaN active trials in "Peak Gastroenterology Associates". undefined are not yet recruiting, 10 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Peak Gastroenterology Associates, undefined suspended trials, and 11 terminated clinical trials to date.

Out of the total trials that were conducted in Peak Gastroenterology Associates, 2 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 31 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".